Table 2.
Activity and efficacy of ROS1 inhibitors in ROS1-TKI naïve NSCLC patients with brain metastases
| Inhibitor reference | Patients n |
mFU months (95% CI) | ORR (95% CI) |
mPFS months (95% CI) |
mDoR months (95% CI) |
mOS months (95% CI) |
|---|---|---|---|---|---|---|
| Crizotinib Wu J Clin Oncol 201831 |
23 | 21.4 (20.1–23.0) | 73.9% (51.6–89.8) | 10.2 (5.6–13.1) | NA | NA |
| Michels J Thorac Oncol 201944 |
6 | 20.6 | 66.7 (22.3–95.7) | 9.4 (1.7–NR) | NA | NR (1.7–NR) |
| Crizotinib Landi Clin Cancer Res 201945 |
6 | 21 (19.0–24.5) | 33.3% | NA | NA | NA |
| Ceritinib Lim J Clin Oncol 201710 |
8* | 14.0 (IQR 9.0–19.0) | 25% (7–59) | NA | NA | NA |
| Lorlatinib Ou WCLC 201815 |
6 | NA | 66.7% (22.3–95.7) | NA | NA | NA |
| Entrectinib Barlesi ELCC 201933 |
23 | 15.5 | 77.4% (63.8–87.7) | 13.6 (4.5–NE) | 12.6 (6.5–NE) | NE (NE-NE) |
| Repotrectinib Cho ASCO 201919 |
3 | 16.4 | 100% (29–100) | NA | NA | NA |
Note: *Considering the entire population (n=32, including two patients previously treated with crizotinib).
Abbreviations: n, Number; mFU, Median follow-up; 95% CI, 95% confidence interval; ORR, Objective response rate; mPFS, Median progression-free survival; mDoR, Median duration of response; mOS, median overall survival; NA, Not available; NE, Not estimable.